Yesterday, after market close, the biotech company Vaxart (VXRT) announced that they have created a scientific and clinical advisory board for assistance on the development of their room-temperature oral vaccines (see link below). This team looks accomplished, and it certainly bodes well for the progress of their potentially disruptive pill vaccine. You don’t assemble (and pay for) this caliber of advisory board unless you have some exciting data in the works and potentially big suitors, like J&J.